20/20 OptimEyes Technologies has developed a mucoadhesive drug delivery platform technology that allows for improved solubility of APIs and extended release. Validated as an eye drop, we have successful pre-clinical studies in glaucoma, dry eye and uveitis.
20/20 OptimEyes Technologies is seeking partners to further develop ophthalmic assets or those with novel or repurposed APIs for co-development opportunities in humans and companion animals. The company is also looking for partners with assets targeting other mucosal areas (nasal, optic, buccal, vaginal or GI).
Intellectual Property
Fundraising
Network with 300+ industry professionals, discover emerging solutions from our innovators, and celebrate entrepreneurship within the Hamilton-Halton ecosystem.
May 1, 2025 | 4:00pm – 8:00pm | Hamilton, Ontario